Gilead Sciences, Inc. (GILD) and Xilio Therapeutics, Inc. (XLO) announced an exclusive license agreement on Thursday to collaborate on Xilio's Phase 1 tumor-activated IL-12 program, XTX301.
Under this agreement, Xilio will be granted $43.5 million in upfront payments, comprising a $30 million cash payment and an initial equity investment of $13.5 million by Gilead in Xilio common stock at a premium.
Xilio stands to earn up to $604 million in additional contingent payments, which involve further equity investments by Gilead, a transition fee, and specific development, regulatory, and sales-based milestones.
Xilio will be responsible for overseeing the clinical development of XTX301 in the existing Phase 1 clinical trial through dose expansion.
Upon submission of a defined clinical data package for XTX301 by Xilio, Gilead will have the option to take over the development and commercialization of XTX301, subject to the terms of the agreement and a $75 million payment by Gilead.
Preceding the potential transition fee, Xilio stands to receive further equity investments of up to $29 million and a development milestone payment.
This transaction is projected to decrease Gilead's GAAP and non-GAAP 2024 earnings per share by around $0.03 - $0.04.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.